Aβ is produced by the cleavage of a large transmembrane protein call the Amyloid Precursor Protein (APP) (Figure 1 ). First, APP is cleaved at a β-site by an aspartyl proteinase referred to as BACE (beta-site APP-cleaving enzyme) [10] [11] [12] [13] [14] [15] . Subsequently, APP is cleaved again at a variable "γ" cleavage site by an enzyme referred to as the γ-secretase (described below) to release peptides ranging from 38-43 amino acids. The γ-cleavage regulates the amount of Aβ produced, as well as the relative amount of the more toxic 42 amino acid form of Aβ. Amyloid precursor protein may also be cleaved at an α position within the Aβ sequence, by an enzyme (or family of enzymes) referred to as α-secretases, which prevents the production of Aβ [16] [17] [18] . β-cleavage is the preferred pathway in neurons 19 . Once produced, individual amyloid peptides (Aβ42 in particular) have a high propensity to form aggregates that begin as small assemblies of dimers and trimers, followed by 'oligomers' and protofibrils, and the large insoluble fibrils that are seen in amyloid plaques 20, 21 .
THE AMYLOID HYPOTHESIS
The literature of AD encompasses numerous pathophysiological mechanisms (reviewed in 22 ) that often seem to be dueling for the status of "most important". Indeed the tissue loss seen in gross pathology of AD ( Figure 2 ) is likely the result of many processes, and not merely the result of deposition of amyloid plaques ( Figure 3) . However, the origins of amyloid hypothesis are not rooted only in pathology, but also in genetics.
Chromosome 21
The genetic view of Alzheimer's disease begins with the longstanding observation that patients with Down's syndrome (Trisomy 21) invariably develop neuropathological features indistinguishable from Alzheimer's disease in early adulthood 23, 24 . This suggested a simple gene-dosage effect caused by an extra copy of a critical gene on chromosome 21. The purification and sequencing of the components in vascular amyloid and amyloid plaques in 1984 lead to the discovery of Aβ 25, 26 and to the subsequent cloning of the APP gene on chromosome 21 27, 28 . The cloning of APP (and subsequent Familial Alzheimer's Disease (FAD) genes below) has allowed their study in cultured cells and the generation of mouse models. In the case of APP, this led to the surprising finding that Aβ production was not a rare pathological event but rather a normal process. Aβ is produced by many cell types and is normally present in plasma and cerebrospinal fluid (CSF) [29] [30] [31] . Synaptic activity regulates the amount of Aβ secreted into CSF 32,33 in mice. In humans, Aβ is also rapidly secreted and cleared from the CSF, presumably governed by similar mechanisms 34 . The next major insight came from families with autosomal dominant Alzheimer's disease (Familial AD-FAD) that occurred well before the age of 65. In some of these families, Alzheimer's Bar 10 μm) disease mapped to the APP gene. To date, 32 mutations (in 86 families) in APP have been described (http://www.molgen. ua.ac.be/ADMutations). These mutations generally fall into three classes. One type of mutation, the Swedish mutation, is located adjacent to the β-cleavage site of APP where it increases the rate of β-cleavage up to 10-fold, resulting in increased production of all amyloid species 35 . Another group of mutations near the γ-site of APP alters the specificity of the γ-secretase cleavage by increasing the relative amount of the more toxic Aβ42 produced (e.g. the London mutation) [36] [37] [38] . In addition, point mutations within the Aβ sequence itself that appear to decrease α-cleavage, increase the stability of Aβ or increase its propensity to aggregate (e.g. the Arctic, Dutch and the Iowa mutations [39] [40] [41] ). FAD can also occur due to increased APP expression due to promoter mutations 42 or by the simple gene duplication of APP [43] [44] [45] . Thus, from the point of view of genetic defects on chromosome 21, anything that increases the amount of Aβ or Aβ42 is tightly associated with AD.
Not just chromosome 21
Even early on, it was apparent that many FAD families mapped outside chromosome 21. A FAD-linked locus was mapped to chromosome 14 by Peter St. George Hyslop's group at the University of Toronto 46 . This led to the identification of mutations in the protein presenilin-1 (PS1) and a second homologous gene on chromosome 1 dubbed PS2 47, 48 . These patients often have additional features such as seizures, myoclonus, long tract signs, ataxia and psychiatric symptoms 49 . With much subsequent work, presenilin was found to be the catalytic protein in a large enzyme complex called the γ-secretase, which is composed of at least 4 proteins (presenilin, nicastrin, mAph1 and PEN2 50-55 ) Recombinant PS1 is able to catalyze γ-secretase cleavage on its own 56 , and mutations at either of two critical aspartate residues in PS-1 and PS-2 within the catalytic site abolishes its enzymatic activity 57 . PS also contains the binding site of pharmacological γ-secretase inhibitors 58, 59 . Currently, mutations in PS1 account for the largest identified group of FAD, with 177 mutations described in PS1 (392 families) and 14 mutations described in PS2 (23 families) (http://www.molgen.ua.ac.be/ADMutations) 60 . While the exact mechanism(s) by which FAD PS mutations alter γ-secretase function remain to be elucidated, they are believed to cause AD by increasing the relative amount of Aβ42 to Aβ40 56,61,62 , even when they reduce the total amount of Aβ produced 63 . The average age of onset in human families correlates with the Aβ42/40 ratio 64 . It is interesting to note that the identification of PS was based solely on genetics with no preconceived notion of their biochemical functions.
Late Onset AD
The genetics of Late Onset Alzheimer's disease has proven more difficult. To date, the best-characterized locus is the Apoliporotein (ApoE) gene. In humans, ApoE has three alleles namely e2, e3, and e4 which differ by only a few amino acids. Individuals with 1 e4 allele are at a 2-3 fold increased risk for Alzheimer's disease and having 2 e4 increases the risk about 12 fold 65 . Some studies suggest that the ApoE2 allele is protective against AD 66 . The mode of action of ApoE also supports the importance of amyloid, as the e4 allele appears to increase the rate of Aβ fibril formation in-vitro 67, 68 and to increase the observed amount of Aβ deposition in mice and humans 69, 70 . More recent evidence suggests that ApoE isoform also controls Aβ clearance from the CSF of transgenic mice 71 . It is estimated that 60-80% of Alzheimer's disease risk may be heritable 72 and many groups are searching for the missing genetic risk factors. In the last few years, new micro-array based techniques of screening referred to as Genome Wide Association Studies (GWAS) have substantially increased the number of candidate genes [73] [74] [75] [76] . The AlzGene database (http://www. alzgene.org/TopResults.asp) currently lists the top ten genes likely to be risk factors for AD. Unfortunately these putative genes (assuming that they prove to be correct) each accounts for only very small risk of AD (Odds Ratio of~1.25) meaning that they are much less powerful than ApoE [73] [74] [75] [76] [77] .
CHALLENGES TO THE ORIGINAL AMYLOID HYPOTHESIS?
Despite the importance of Aβ, there were a number of important drawbacks to the original Amyloid Hypothesis. The most serious of these were that amyloid plaque load does not correlate well with cognitive function or disease progression in humans 78, 79 or mice 80 . In fact, neurofibrillary tangles (NFT's) correlated better with cognitive impairment, leading many to suspect they might be the critical causative agent in AD 78, 79 .
Tangles: the fall and the return
Neurofibrillary tangles (NFTs) are made up of intracellular aggregates of paired helical filaments of the protein tau, which have become hyperphosphorylated 78, 79 ( Figure 3 ). Although NFT's correlate well with AD onset and progression 81 , to date, no tau mutations have been found in AD families. Instead, tau mutations cause phenotypically distinct diseases including frontotemporal dementia, which do not display plaques, suggesting that tau pathology in AD is downstream of Aβ 79, 82 . This idea also is supported by pathological studies in Down syndrome and transgenic mice that demonstrate that amyloid plaques precede the appearance of NFT's 83, 84 . Furthermore, treatments that increase Aβ oligomers in mouse models lead to increased tau pathology [85] [86] [87] [88] . Conversely, immunotherapy to deplete Aβ clears amyloid plaques and reduces early tau aggregates, although later stage tau aggregates are not reversible 87 . Other experiments suggest that tau does have a role in AD as reducing tau levels or disrupting tau's interactions with signaling proteins reduces pathology and improves memory [89] [90] [91] . Therefore, tau is likely still important in AD, but its effects are downstream from Aβ.
Amyloid: Are Plaques a distraction?
Although amyloid plaques might be the most striking aspect of AD pathology (Figure 3 ), the best pathological correlate of cognitive impairment is loss of synapses [92] [93] [94] [95] . Synaptic loss correlates not with insoluble amyloid fibrils in plaques but with levels of soluble amyloid species in the brain 96.97 . Aβ are now recognized to aggregate into a wide variety of soluble structures, from simple dimers and trimers to large soluble oligomers sometimes referred to as Amyloid Derived Diffusible Ligands (ADDLs) and Aβ56* 95, [98] [99] [100] . These soluble aggregates are orders of magnitude more toxic to neurons and synapses than the insoluble amyloid fibrils in plaques 20.21 . In animal models, soluble Aβ impairs learning performance and decreases the number of synapses [100] [101] [102] . These changes are reversible through clearing or antibody chelation of Aβ [103] [104] [105] . Furthermore, oligomeric Aβ binds directly to synapes containing glutamate neurotransmitter receptors (including N-methyl D-Aspartic Acid (NMDA) receptors) causing a rapid decrease in receptors, reducing signaling, disrupting the structure of the synapse 99, 103, 106, 107 and depleting synaptic vesicles 108 . Aβ oligomers have also been proposed to impair LTP by binding to the prion protein (PrP) [109] [110] [111] although this is currently controversial 105, 112 . It is these small soluble amyloid oligomers that are now the main focus of the Amyloid Hypothesis.
INTRACELLULAR AMYLOID. THE OTHER HALF?
While the discovery of soluble amyloid aggregates may explain the acute effects of amyloid toxicity, it might not explain more chronic changes of AD including alterations of neuronal structure, neuronal loss, or the origin of plaques. One possible inroad to understanding these changes comes from the study of Aβ aggregation inside living cells.
The endosomal/ lysosomal system comprises a series of intracellular compartments that are responsible for taking up extracellular material and proteins from the cell surface. Internalized material is transported to early endosomes, where they are sorted, and then either recycled to the cell surface or transported to late endosomes/ multivesicular bodies and then to lysosomes (See Figure 4) . A parallel system called macroautophagy (referred to hereafter as autophagy) provides a parallel pathway for the degradation of long-lived intracellular proteins and organelles such as mitochondria. Autophagy begins with double-layered sheets of membrane arising from the endoplasmic reticulum engulfing regions of cytoplasm to form double walled autophagic vesicles. These vesicles may then fuse with endosomes to acquire hydrolytic (digestive) enzymes, and eventually fuse with lysosomes 113, 114 . Lysosomes are highly acidic (pH 4.5) compartments containing > 80 hydrolytic (digestive) enzymes. [115] [116] [117] [118] . Lysosomes are recognized clinically because of more than 40 Lysosomal Storage Diseases (LSDs), which are usually caused by the absence of a critical catabolic (digestive) enzyme resulting in a buildup of undigested material in lysosomes. When they involve the central nervous system, these diseases lead to dementia and death 119 . Although lysosomes are traditionally thought of as simply a waste disposal/digestive system, they are now also recognized as a secretory compartment in a wide variety of cell types including thyroid hormone, pulmonary surfactant, albumin, cytotoxic compounds from lymphocytes and neurtrophils [120] [121] [122] . Lysosomes are also able to fuse with the cell membrane in order to repair damage to the cell surface 123 . The endosomal/ lysosomal system plays a role in Aβ production. This was best demonstrated in experiments in which APP is labeled on the cell surface and followed as it is internalized, cleaved into Aβ, and then secreted or retained intracellularly [124] [125] [126] [127] [128] . Moreover, increasing the rate of internalization of APP increases Aβ generation, and blocking internalization reduces Aβ levels 32, 125, [129] [130] [131] [132] [133] [134] [135] [136] [137] . Autophagosomes have also been demonstrated to contain APP, β-and γ-secretases and to produce Aβ 138, 139 . Our own work has demonstrated that APP and γ-secretase activity are highly enriched in lysosomes 140, 141 . We have also found that APP undergoes unexpectedly rapid direct transport to the lysosome from the cell surface 142 and from internal compartments and these pathways may play a role in Aβ production (unpublished observations) 143 . Although the spontaneous intracellular accumulation of Aβ42 has long been recognized in cultured neuronal cells [144] [145] [146] [147] [148] , the histological detection of intracellular Aβ in tissue has only been recognized relatively recently. This is likely because the standard techniques used to immunostain amyloid plaques rely on concentrated formic acid; formic acid improves appearance of plaques, but can wash away intracellular deposits [149] [150] [151] . Reliable detection of intracellular Aβ therefore requires optimizal tissue preparation techniques (antigen retrieval) along with careful selection of highly specific, high affinity antibodies 152 (reviewed in 153 ). Although it still has detractors 154 , the concept of intracellular Aβ accumulation is now widely accepted 153, [155] [156] [157] . Figure 3 shows examples of extracellular and intracellular Aβ.
Intracellular accumulation of Aβ42 in the endosomal/ lysosomal system has been observed in transgenic Alzheimer's disease mice either before or accompanying cognitive impairment, but well before the appearance of amyloid plaques [158] [159] [160] [161] [162] [163] [164] [165] [166] . Intracellular Aβ42 has been shown in human 171, 172 . The intracellular accumulation of Aβ may play a role in AD pathology. This is because Aβ fibrils found in plaques are preferentially nucleated by both lysosomal gangliosides (complex lipids and carbohydrates) and the lysosomal pH of 4.5 [173] [174] [175] [176] [177] . Furthermore, in-vitro experiments demonstrate that Aβ fibril formation directly disrupts lipid membranes 175, 178 . These effects come together in experiments that show Aβ taken up from the media can nucleate further Aβ aggregation 155, [179] [180] [181] [182] . From there, it can directly disrupt the structures of neurons and synapses 183 or cause lysosomal rupture leading to cell death 184, 185 . Cell death is likely due to the release of digestive enzymes into the cytoplasm, or their secondary activation of programmed cell death pathways 143, 186 . The propensity for Aβ to aggregate in the acidic environment of the lysosome suggests that extracellular amyloid plaques may begin as amyloid 'seeds' in the lysosome. This idea is supported by evidence that cell death begins only after intracellular Aβ42 is detected 187 and that the amount of intracellular Aβ42 decrease as plaques appear 164, 188 . In addition, the presence of many active lysosomal enzymes in plaques suggests that lysosomal contents directly contributed to plaques [189] [190] [191] [192] . Furthermore, remnants of neuronal cell bodies are often seen in the center of mature 'dense core' plaques suggesting that these cells were lysed to form the beginnings of the plaque 167, 193 . Recent experiments using confocal microscopy in live mouse brains have demonstrated that plaques can appear rapidly over 24 hours 194 , confirming that plaques can appear acutely.
A different route to pathology in AD?
Abnormalities in the endosomal/lysosomal system have been recognized in Alzheimer's disease pathological material since the early 1990's. Even before the onset of clinical disease, there is a marked increase in the number and size of lysosomes in brain regions most vulnerable to Alzheimer's disease. As Alzheimer's disease advances, lysosomes multiply and appear to fill neurons 115, 191, [195] [196] [197] . Using electron microscopy, it is now recognized that many of these compartments are autophagic vacuoles that are also undergoing massive upregulation 138, 198 . In fact, the dystrophic neurites characteristic of AD are actually neuronal processes filled predominantly with autophagic vacuoles 199 . Autophagy in neurons is highly efficient and autophagosomes are not normally observed, and their appearance suggests a pathological failure of this system 200 . The accumulation of lysosomes and autophagosomes in AD is strikingly similar to the pathology seen in Lysosomal Storage Diseases (LSDs) 199 . These diseases are also accompanied by a prominent failure of autophagy 119, 199 , and the failure of autophagy can cause neurodegeneration on its own 201 and may represent a mode of cell death 119 . Conversely, the failure of the lysosomal system in a number of LSD's can also lead to elevated levels of Aβ and tau; these include Niemann-Pick Type C 202 , Tay Sach's and Sandhoff's disease 203 and mucopolysaccharidosis 204 . These effects can be partly replicated experimentally; inhibiting lysosomal proteolysis causes buildup of autophagic vacuoles in processes very similar to AD 205 , and overloading cells with gangliosides inhibits APP degradation and increases Aβ production 203, 206 . Recently, PSs have emerged as a potentially unifying factor in these pathologies. PS1 is important for clearance of proteins from endosomes 207 , for clearance of proteins by autophagy 199, 208, 209 and for trafficking through the endosomal lysosomal system 210 . In a recent twist, PS mutations have been shown to directly impair lysosomal function by preventing lysosomal acidification 211 suggesting that FAD might be in effect a Lysosomal Storage Disease. Thus, PS mutations can lead to cell death by two different pathophysiological processes. On the one hand they are responsible for producing toxic Aβ species, and on the other hand they block autophagy, impairing the cell's ability to clear Aβ (and perhaps tau).
Defects in autophagy and intracellular Aβ clearance may represent a therapeutic target. This was shown dramatically in recent experiments in which knocking-out an endogenous lysosomal protease inhibitor (cystatin B) increases the clearance of intracellular Aβ, reduces the number of autophagic vesicles, decreases plaques, and prevents the development of cognitive changes 212 . A number of 'lysosomal modulatory' drugs are under study, that increase the levels of lysosomal enzymes and appear to reduce Alzheimer's pathology in a tissue slice model of AD 213, 214 . Taken together, these data suggest that in addition to the acute extracellular effects of Aβ oligomers, Aβ also accumulates intracellularly as either a cause or a consequence of lysosomal dysfunction, which results in neurons exhibiting neuropathological changes reminiscent of classic LSD. These intracellular changes can cause pathology independently from the acute synaptotoxic effects of extracellular Aβ oligomers. Amyloid plaque formation might be secondary to neuronal lysis and release of intracellular Aβ.
CONCLUSIONS: WHERE TO FROM HERE?
Although the Amyloid Hypothesis has gone through a number of twists and turns, amyloid still appears to be an important causal factor in AD. However, the true proof of this model will ultimately rest on whether amyloid-reducing therapies can treat Alzheimer's disease. A large number of compounds are currently in clinical trials. Generally antiamyloid treatments fall into several classes, including compounds that inhibit Aβ production (by inhibiting secretase enzymes) and compounds which bind Aβ to impair aggregation, neutralize toxicity or increase clearance 215, 216 . These include antibody-based strategies of active immunization and passive immunization with monoclonal or polyclonal antibodies 87, [217] [218] [219] [220] [221] [222] , or small molecules such as Scyloinositol 223 . Although these strategies are effective in treating mice, there have been a number of high profile failures in clinical trials, including Tarenflurbil and LY451039 (secretase modulators/ inhibitors) and Alzmed (tramiprosate; an aggregation inhibitor) 224 . In addition, we know from a discontinued Aβ vaccination trial in humans, that clearance of Aβ plaques alone is not sufficient to improve symptoms 225, 226 .
Some have taken these failures to mean that there is a problem with the Amyloid hypothesis itself. Before coming to that conclusion, we must first look at the limitations of these trials. Currently, AD is a clinical diagnosis, made only after the appearance of cognitive impairment. However, AD has a long presyptomatic phase suggested to be years to decades 227, 228 , during which neuropathological changes and subtle cognitive and imaging changes can be observed [229] [230] [231] [232] . While the transition from presymptomatic disease to AD is difficult to identify clinically, it is important to be able to do so, because neuronal loss begins at the earliest clinical changes of AD (transition from a Clinical Dementia Rating scale score (CDR) of 0 (asymptomatic) to a CDR of 0.5 (very mild dementia) 233, 234 . Numerous biomarkers are under study to try to detect or predict this transition to AD. These include CSF protein levels (tau and Aβ), volumetric MRI to quantitate atrophy, and nuclear medicine-based scans of brain glucose uptake and amyloid load (e.g. Pittsburgh compound or PiB scans). Although these are promising, they are still considered research tools 227, [235] [236] [237] [238] . From animal studies, we know that even modest reductions in Aβ production can dramatically reduce amyloid deposits and improve memory 165, 223 , but only early pathology may be reversible 87 . In humans, a number of other factors will likely complicate clinical applications. For example, amyloid found in human brains is much more insoluble than amyloid produced in mice, 239 suggesting that it will be more difficult to clear. In addition, the γ-secretase also processes a large number of other important regulatory proteins (most notably the Notch receptor) and inactivation is toxic in many tissues and lethal to embryos [240] [241] [242] . A safe γ-secretase inhibitor will need to selectively block Aβ production without impairing its other functions. It must also be pointed out that the failed trials were first generation agents which had significant technical limitations and were advanced to phase 3 trials without being successful in phase 2 trials 224 . More concerning, however, is that transgenic mice used to develop these treatments generally do not exhibit the high levels of neuronal loss seen in AD. In fact, it has been argued that transgenic mice only model early AD, while the trials were looking at established AD 224 . This fundamental mismatch between the mouse models and the human patients might therefore be the largest obstacle for the therapeutic application of the Amyloid Hypothesis.
It may be that that anti-amyloid agents will only be effective if they are used before irreversible damage has occurred, or in other words before symptoms appear. Therapeutic trials may not work without better diagnostics to allow identification of patients with presymptomatic or very early AD, 224 . With the oncoming tidal wave of patients, the cost of failure to treat or cure Alzheimer's disease will be staggering. If we are to affect the course of AD, safer and more effective amyloid lowering treatments will need to be coupled with better, earlier, presymptomatic diagnosis. 
